Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)

B SHANGHAI, April 15, 2026 /PRNewswire/ — Mabwell (688062.SH), an innovative biopharmaceutical company with a full industry chain, announced that the National Medical Products Administration…
posteditor
posteditor
Articles: 16137

Other News